The HCC Phase III trial enrollment is about six months ahead of schedule. This is important news, but the Market doesn't seem to care. The Market assigns a zero probability of success to the trial.
NIH showed a statistically significant PFS in a Phase II trial in prostate cancer with Tivantinib as a single agent. Again, the Market gave a collective yawn, possibly because investors remember EXEL's Cabo, which also showed good results in a Phase II and then failed on OS in the Phase III. Cabo was also a MET inhibitor. Not sure if Daiichi and the NIH will take this into a Phase III, but it remains a possibility.
ARQL has three proprietary molecules, ARQ-092, ARQ-087 and ARQ-791, all in the clinic. Pre-clinical results will be presented in seven presentations at EORTC on November 18-21. ARQL will have a CC after the presentations.
Cash runway will extend in 2017.
All this for a company with an EV only slightly above zero. Amazing.
I think so. I own a ton, but I've been wrong about the stock for two years. Nonetheless, I think the HCC trial has a decent chance of success; the Phase II data looks impressive to my untrained eye. Perhaps more importantly in the short term, the proprietary pipeline, especially the Akt inhibitor, looks very good, according to Ohad Hammer. Since he just put a ton of money in my pocket with AMBI--I tendered my shares today--I tend to trust him a lot. I spoke to IR today. There will be a 3rd quarter earnings call on November 10th and a later CC to discuss the presentations at EORTC. I expect the stock price to move up on the news. In any case, this company shouldn't be trading with a negative EV, IMO
What make you so sure that it is the chemotherapeutic warhead and not the (folate) recepetor that is the problem? (I'm going to assume it's not the linker technology, since that technology comes from a leader in field, Seattle genetics.)
Cantor Fitzgerald initiated coverage on MEI Pharma (NASDAQ: MEIP) with a Buy rating and a price target of $14.00.
Analyst Daniel Brims said, "We are initiating coverage of MEIP with a BUY rating and $14 price target, which is based primarily on lead drug candidate Pracinostat’s expected peak revenue of $700M in two indications, MDS and AML. We forecast the commercial launch of Pracinostat in 2017/2018 contributing $10/share to our valuation. MEIP has initiated three Phase 2 trials to assess Pracinostat in front-line AML and MDS, as well as refractory MDS, and we expect several important catalysts for Pracinostat during 4Q:14. Beyond Pracinostat, MEIP is also developing ME-344, which is in Phase 1B testing for small cell lung and ovarian cancer, and PWT-143, a preclinical PI3 Kinase inhibitor. We have assigned $3/share and $1/share in value, respectively, due to the early stage of development of these assets."